

Jim Christensen, MD

PROFESSIONAL DATA

Pulmonary Associates
7200 Cathedral Rock Drive
Ste. 220
Las Vegas, NV 89128
(702) 307-7707 (phone)
(702) 307-7706 (fax)

Pulmonary Associates
4 Sunset Way
Bldg. A-Ste. 3
Henderson, NV 89014
(702) 434-9690 (phone)
(702) 436-7266 (fax)

Wellness Center
2300 S. Rancho Dr. #205
Las Vegas, NV 89102
(702) 383-2691 (phone)
(702) 388-4186 (fax)

Nevada Access to Research and Education Society (NARES)
Nevada AIDS Research and Education Society
2300 S. Rancho Dr. #203
Las Vegas, NV 89102
(702) 384-9101 (phone)
(702) 384-9109 (fax)

E-mail address:	snotdoc@cox.net
UPIN:	E 41200
MEDICARE:	WJBCQ02
MEDICAID:	2019060
MEDICAL EDUCATION #:	03101840068
NATIONAL PROVIDER IDENTIFIER #:	1700830015

EDUCATION AND DEGREES

1974 - 1978	University of California Irvine, CA B.A. Chemistry
1977 - 1978	University of California Irvine, CA Physical Science Research Fellow
1980 - 1984	University of Nevada School of Medicine Reno, NV Medical School
1984 - 1987	Washington University at St. Louis St. Louis, MO Internal Medicine, Internship and Residency
1985	Diplomat, NBME
1987	Diplomat, American Board of Internal Medicine
1987 - 1989	National Jewish Center of Immunology and Respiratory Medicine Denver, CO Fellowship, Allergy and Immunology
1989	Diplomat, American Board of Allergy and Immunology Re-certified 1999
1994	Diplomat, American Board of Utilization Review and Quality Assurance
1997	Fellow, American College of Physicians

LICENSURE

California	#G059835	04/06/1987
Arizona	#18649	04/14/1989
Nevada	#6171	12/01/1990

MILITARY DUTY

1987 - 1992	Major, U.S. Air Force Reserve Medical Corps
1988 - 1992	Flight Surgeon 120 th TFS Colorado Air National Guard

EMPLOYMENT HISTORY

1978 - 1979	Craps Dealer Las Vegas, NV
1979 - 1980	Emergency Medical Technician Las Vegas, NV
1984 - 1987	Intern, Junior and Senior Assistant Resident Department of Internal Medicine Washington University of St. Louis St. Louis, MO
1987 - 1989	Clinical Fellow Allergy & Clinical Immunology National Jewish Center Denver, CO
1989 – Oct 1990	Private Practice Allergy and Immunology Associates Scottsdale, AZ
Oct. 1990 - Dec. 1990	Urgent Care Department Cigna Health Plan of Arizona Phoenix, AZ
Dec. 1990 - Dec. 1992	Assistant Professor of Medicine Assistant Program Director Department of Internal Medicine University of Nevada School of Medicine Las Vegas, NV
Dec. 1992 – Oct. 2006	Allergy and Asthma Associates Las Vegas, NV
April 1994 - Present	Co-Founder, NARES Las Vegas, NV

EMPLOYMENT HISTORY

Nov. 2006 – Present Pulmonary Associates
Las Vegas, NV

ACADEMIC APPOINTMENTS

1990 - Present Clinical Assistant Professor
Department of Internal Medicine
University of Nevada School of Medicine

1997 - Present Clinical Associate Professor
Department of Health Sciences
University of Nevada Las Vegas

2005- Present Adjunct Professor
Department of Primary Care
Touro University/Henderson Nevada

HOSPITAL STAFF AFFILIATIONS

University Medical Center of Southern Nevada	Las Vegas, NV
Valley Hospital	Las Vegas, NV
Sunrise Medical Center	Las Vegas, NV
St. Rose Dominican Medical Center	Henderson, NV
St. Rose Dominican–Siena Campus	Henderson, NV
Spring Valley Hospital Medical Center	Las Vegas, NV

PROFESSIONAL APPOINTMENTS

1998 – Present Physician at Large Member
Clark County Board of Health

1999 – Present Chairman, Performance Improvement Committee
University Medical Center of Southern Nevada

2002 – Present American College of Physicians
Governor, State of Nevada

2002 – Present Chairman, Department of Medicine
University Medical Center of Southern Nevada

2003 Director of Performance Improvement
Spring Valley Hospital Medical Center

PROFESSIONAL APPOINTMENTS

2006 – Present Vice Chief of Staff
University Medical Center of Southern Nevada

COMMUNITY ORGANIZATIONS AND AWARDS

1991 - 1998 Medical Director, Asthma Camp

1998 - 2000 President, Board of Directors Reach Out

2000 Leadership Las Vegas, Graduate
Las Vegas Chamber of Commerce

2000 Humanitarian of the Year
Las Vegas Chamber of Commerce

2000, 2002,
2004 Top Doctor's of Las Vegas
Las Vegas Life Magazine

MEMBERSHIPS AND ASSOCIATIONS

American College of Physicians
American Academy of Allergy and Immunology
American College of Allergy and Immunology
Clark County Medical Society
American Academy of HIV Medicine

PUBLICATIONS

Hamilos DL, Christensen J, Bean DK, Treatment of Churg-Strauss Syndrome with High-Dose Intravenous Immunoglobulin. JACI 1991; 88:823-4.

Bishop P, Wisnieske JJ, Christensen J, Hypocomplementemic Urticarial Vasculitis: A case report and review of the literature. West J Med 1992; 159:605-8.

Wisnieske JJ, Baer AN, Christensen J, et al. Hypocomplementemic Urticarial Vasculitis Syndrome: A prospective & retrospective study of 18 patients. Medicine 1995; 74:24-41.

Church JA, Mitchell WG, Ganzales-gomez I, Christensen J, et al. Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. J Pediatr 2001;138: 748-51.

RESEARCH

Deflazacort in mild Asthma. Principal Investigator. 1988

566C80 (Mepron) in Pneumocystis Carinii Pneumonia. Investigator. 1991

ABT-971. Phase III Study of the effects of Zileuton, 400 and 600mg QID compared to Beclomethasone in asthma. Investigator. Abbott Laboratories. 1993.

FLTA 2005. A trial of inhaled Fluticasone MDPI vs. Placebo in adolescent and adults with asthma. Investigator. Glaxo Welcome. 1993.

RG-5016T-203. Study of Azmacort HFA-134a compared to Azmacort in the treatment of asthma in children. Investigator. Rhone-Poulenc Rorer.

RG-5016Y-203. Study of Azmacort HFA-134a compared to Azmacort in the treatment of asthma in adults. Principal Investigator. Rhone-Poulenc Rorer.

04-3100. Study of Budesonide nebulizing suspension and Placebo in asthmatic children age eight and younger. Investigator. Astra Pharmaceuticals

04-3100. Open label extension. Study of Budesonide nebulizing suspension and Placebo in asthmatic children age eight and younger. Investigator. Astra Pharmaceuticals

FLTA-2005. Open label extension. A trial of inhaled Fluticasone MDPI vs. Placebo in adolescent and adults with asthma. Investigator. Glaxo Welcome.

Azithromycin. Oral/Intravenous Azithromycin Treatment of Cryptosporidiosis in Patients Whose Disease has not been Controlled by Conventional Therapy (066-167S). Investigator, Premier Research.

Amphotericin B Lipid Complex (ABLC) for Companionate Use (A93-D-01, 339). Investigator, The Liposomal Company, Inc.

Saquinavir. HIV Proteinase Inhibitor Saquinavir Ro 31-8959 (SV14604). Investigator, F. Hoffmann LaRoche Limited.

Saquinavir Ro 31-8959 A Continuation Protocol with Open Label Saquinavir for HIV-Infected Patients Who Have Completed a Clinical Trial with Saquinavir Treatment (SV14788). Investigator, F. Hoffmann LaRoche Limited.

Lamivudine. 3TC (Lamivudine) Open Label Program (NUCA 3004). Investigator, Glaxo, Inc.

RESEARCH

Vistide (Cidofovir). IV Treatment IND Protocol for Relapsing Cytomegalovirus Retinitis in Patients with AIDS (GS 95120). Investigator, Gilead Sciences.

Albendazole (Eskazole) for Compassionate Use in Microsporidiosis (IND 45062). Investigator, SmithKline Beecham.

Ambisome. Compassionate Use of Ambisome for Treatment of Invasive Fungal Infections in Patients Intolerant to, or with, Disease Unresponsive to Standard Antifungal Therapy (95-0-010). Investigator, Fujisawa USA.

Nevirapine (Viramune). An Open Label Non-Randomized Trial to Evaluate the Tolerability and safety of Viramune (nevirapine) in Adult and Pediatric Patients with Progressive, Symptomatic HIV Disease. Protocol 1100.859. Investigator, Roxanne.

Viracept. Viracept Expanded Access Program (Ind# 48.124). Investigator, Auguron.

Synercid. Open Study of Synercid (Quinupristin/Delfopristin, RP 59500) for Emergency Use (Infections Due to Resistant Bacteria Treatment Failure or in Treatment Intolerant Patients). Protocol JRV 398. Investigator, Rhone-Poulenc Rorer.

Indinavir (Crixivan). A Noncomparative, Multisite, Open-Label, 48-Week Study to Monitor the Safety and Tolerability of MK-0639 (Indinavir Sulfate) 800mg q8h Administered as Monotherapy or in Combination with Reverse Transcriptase Inhibitor Therapy for the Treatment of HIV-1 Infection in Advanced AIDS Patients (Patients with CD4 Counts $<50\text{cells}/\text{mm}^3$ (99-00)). Investigator, Merck and Co., Inc.

Mycobutin (Rifabutin). An Open-Label Randomized Pharmacological/ Pharmacodynamic study of mycobutin (Rifabutin) monotherapy, and in combination with myambutal (Ethambutal), for prophylactic use in prevention of Mycobacterium-Avium Complex (MAC) bacteria in AIDS patients with CD4 count $\leq 100\text{mm}^3$. Investigator, Pharmacia.

Nitazoxanide. Open-Label Compassionate Use of Nitazoxanide for the treatment Of Cryptosporidiosis in AIDS patients. Protocol UMD-95-009. Investigator, Unimed Pharmaceuticals.

Viracept. An Open-Label Study to Evaluate Viracept Treatment of HIV-Infected Children Who Could Benefit from a Protease Inhibitor Based on Clinical or Immunologic Status (AG1343-546). Investigator, Aguoron.

RESEARCH

A 1592U89 Open Label Protocol of Adult Patients with HIV-1 Infection (CNA/3008). Investigator, Glaxo Wellcome Research & Development.

Thalidomide. Treatment of Aphthous Ulcers in a Patient with Behcet's Syndrome, having Failed Steroid and Immunosuppressive Therapy (IND# 53,970). Investigator.

Saquinavir. A Randomized Phase IIIB Comparative Study to Evaluate Saquinavir Soft Gel Capsules (SGC) TID Regimen in Combination with two NRTI's Versus Saquinavir Soft Gel Capsules (SGC) BID Regimen in Combination with two NRTI's Versus Saquinavir Soft Gel Capsules (SGC) BID plus Nelfinavir BID plus an NRTI in HIV-1 Infected Patients (NR5520B/M51018). Investigator, F. Hoffmann-La Roche LTD.

A 1592U89 Open Label Protocol for Pediatric Patients with HIV Infection (CNA/3007). Investigator, Glaxo Wellcome Research & Development.

Sustiva (efavirenz). Expanded Access Program DMP266-903 (IND# 49,465). Investigator, DuPont Merck.

Thalidomide. Treatment of Aphthous Ulcers in a Patient with Behcet's Syndrome Having Failed Steroid and Immunosuppressive Therapy (IND# 54,463). Investigator.

A Multicenter Open Label Randomized 24-Week Study to Compare the Safety and activity of Indinavir Sulfate 800mg Q8H Versus 1200mg Q12H in HIV-Infected Individuals Having Plasma Viral RNA Less Than 400 copies/ml on Concomitant Therapy with Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTI) 076-00. Investigator, Merck & Company.

Preveon Expanded Access Program for the Treatment of Patients with AIDS Who Have Failed Other Antiretroviral Therapy and have Limited Treatment Options (GS-52-427). Investigator, Gilead Sciences.

An Open-Label Multicenter Study to Assess the Safety and Antiviral Activity of a Twice-Daily Dosing Regimen of Viracept Combined with Two Reverse Transcriptase Inhibitors in HIV-Infected, Treatment Naive Patients (AG13543-1022). Investigator, Auguron

Compassionate Use of Thalidomide in Hypocomplementemic Urticarial Vasculitis Syndrome (IND 55,590), Investigator.

RESEARCH

The Thalidomide Compassionate Use Program. Compassionate Use of Thalidomide in Adults with HIV-Associated Wasting (W-002). Investigator, Celgene Corp. 1998.

Amprenavir (141W94). Open label protocol for patients with HIV-1 infection who have experienced treatment failure or are intolerant to protease therapy, (PR030010). Investigator, Glaxo Wellcome, Dec., 1998.

A Phase III trial to determine efficacy of bivalent AIDSVAX™ B/B vaccine in adults at risk for sexually transmitted HIV-1 infection in North America (VAX004). Investigator, Vaxgen Inc., March, 1999.

Evaluation of the safety and antiviral activity of stavudine extended release Formulation as compared to stavudine immediate release formulation, each as part of potent antiretroviral combination therapy. (AI455-096). Investigator, Bristol-Myers Squibb, Oct 1999.

DE 009. A multicenter randomized placebo controlled phase II study of the Human Anti-TNF Antibody D2E7 administered as subcutaneous injections in rheumatoid arthritis patients treated with methotrexate. (LU 200134). Investigator, Knoll Pharmaceutical Comp, Dec 1999.

O99009 Transdermal oxybutynin in patients with urge urinary incontinence: A 12 week multicenter, randomized, double-blind, placebo-controlled study with a 12-week open-label, dose-titration, safety extension. Watson Laboratories. Investigator, Jan 2000.

Protocol M99-046. ABT-378/r (ABT-378/ritonavir) Early Access Program. Investigator, Abbott Laboratories, Jan 2000.

SNG477. A randomized, double-blind, multicenter study to evaluate the effect of adding either Montelukast Sodium or Salmeterol Xinafoate to inhaled Fluticasone in adult asthmatics. Principal Investigator. Merck and Co. Inc.

A randomized, double-blind, placebo controlled, parallel-group 12 week trial evaluating the safety and efficacy of Salmeterol/Fluticasone Propionate combination in GR106642X MDI vs. Salmeterol, Fluticasone or Placebo in adolescent and adult subjects with asthma. Investigator. Glaxo Wellcome. 2000.

Protocol ESS 40001 A Phase IV, open-label, randomized study to compare the efficacy and safety of Efavirenz/Ziagen/Zerit versus Efavirenz/Ziagen/Sustiva versus Efavirenz/Ziagen/Agenerase/Norvir for 96 weeks in the treatment of HIV-1 infected subjects who are Antiretroviral therapy naive. Glaxo Wellcome. Investigator, Aug 2000.

RESEARCH

Protocol ESS 40009 Ziagen Optimal Regimen and Resistance Observational Study. A Phase IV, Open-label study to assess the safety and tolerability of abacavir (Ziagen), in HIV-1 infected individuals and to investigate the effect of baseline genotype with virtual phenotype on the response to abacavir (Ziagen) in therapy experienced subjects in the clinical setting. GlaxoWellcome Research and Development. Investigator, Aug 2000.

HMP-3006 A Study of the Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release (HHER) Compared to Placebo in Patients with Chronic Pain. Purdue Pharma L.P. Principal Investigator. Jan 2001.

AI455-110. A Study to Compare Stavudine (D4T) Extended Release (ER) versus Conventional (Immediate Release, IR) Formulations, Each in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Subjects who have Completed BMS Studies AI455-096 and AI455-099. Bristol-Myers Squibb. Investigator Jan 2001.

ESS40013. A Phase IV Multicenter Study of the Efficacy and Safety Of 48-Week Induction Treatment with Trizivir + Efavirenz Followed by 48-Week Randomized, Open-Label Maintenance Treatment with Trizivir ± Efavirenz in HIV-1 Infected ART Naïve Subjects. GlaxoSmithKline. Investigator Mar 2001.

HIV-TE-Evaluation Project 101. An Evaluation of the Use of the HIV-Therapy Edge (HIV-TE) Service in the Management of HIV-Positive Patients Currently Failing Antiretroviral Drug Therapy. Intelligent Therapeutic Solutions, Inc. Investigator May 2001.

O00011. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing Oxybutynin Transdermal Systems versus Tolterodine Long Acting Capsules in Patients with Overactive Bladder. Watson Laboratories. Investigator May 2001.

CNA30021. A phase III, 48 week, randomised, double-blind, multicentre study to evaluate the safety and efficacy of abacavir (ABC) 600mg once-daily(QD) vs abacavir 300mg BID in combination with lamivudine (3TC) (300mg QD) and efavirenz (EFV) (600mg QD) in antiretroviral therapy Naive HIV-1 infected subjects. GlaxoSmithKline. Investigator 2001.

SPORTIF V. Efficacy and safety study of the oral direct thrombin inhibitor H376/95 compared with dose-adjusted warfarin (Coumadin) in the prevention of stroke and systemic embolic events in patients with atrial fibrillation. Astra Zeneca. Principal Investigator. 2001.

RESEARCH

N91-00-02-079. Clinical protocol for a randomized, double-blind, placebo controlled, parallel group comparison of the analgesic activity of valdecoxib (SC-65872) 20mg bid versus diclofenac 75mg bid in patients with chronic cancer pain. Pharmacia/Pfizer. Principal Investigator. 2001.

N49-01-02. clinical protocol for the assessment of the efficacy of treatment by Celecoxib 200mg QD and 400mg QD on the symptoms of ankylosing spondylitis compared to naproxen and placebo. Principal Investigator. Pharmacia. 2001.

HMR3647A/3014. Randomized, open-label, multicenter trial of the safety and effectiveness of Oral Telithromycin (Ketek) and amoxicillin/clavulanic acid (Augmentin) in outpatients with respiratory tract infections in usual care settings. Aventis Pharmaceuticals, Inc. Principal Investigator. 2001.

NAVIGATOR Nateglinide/CDJN608B. A multinational, randomized, double-blind, placebo-controlled, forced-titration, 2 X 2 factorial design study of the efficacy and safety of long term administration of nateglinide and valsartan in the prevention of diabetes and cardiovascular outcomes in subjects with impaired glucose tolerance. Novartis. Principal Investigator.

CLAF237A 2203. A 12 week, multicenter, double-blind, randomized, parallel-group, dose-ranging study to assess the efficacy, safety and tolerability of LAF237 25mg bid, 25mg, 50mg, 100mg qd compared to placebo in patients with type 2 diabetes. Novartis. Principal Investigator.

SAS40036. Multicenter, randomized, double blind, double dummy, parallel group 16 week comparison of asthma control in adolescents and adults receiving either Fluticasone Propionate/Salmeterol Diskus 100/50mcg bid, Fluticasone Propionate Diskus 100mcg bid, Salmeterol 50mcg bid or montelukast 10mg qd. GlaxoSmithKline. Principal Investigator.

M016455P/3003. A multicenter, open label, randomized, parallel group study to assess the long term safety, performance, and efficacy of fexofenadine compared to montelukast in subjects with asthma. Aventis. Principal Investigator. April 2002.

SAS30022. A randomized, double-blind, placebo-controlled, parallel-group, 12 week trial evaluating the efficacy and safety of the Fluticasone Propionate/Salmeterol Diskus combination product 250/50mcg once daily versus Fluticasone Propionate/Salmeterol Diskus combination product 100/50mcg twice daily versus Fluticasone Propionate Diskus 250mcg once daily versus placebo in symptomatic adolescent and adult subjects with asthma that is not controlled on short acting beta 2 agonists alone. GlaxoSmithKline. Principal Investigator. 2002.

RESEARCH

AI424-045. A randomized, open label study of the antiviral efficacy and safety of atazanavir, in combination with ritonavir or saquinavir, and the combination of lopinavir each with tenofovir and a nucleoside in subjects who have experienced virologic failure. Bristol-Myers Squibb. Investigator April 2002.

CFOR258D2307. A randomized, multicenter, placebo controlled, parallel group study, of four month duration per patient, to evaluate the safety and efficacy of treatment with 24mcg bid and 12mcg bid formoterol double blind and 12mcg bid formoterol with additional on demand formoterol doses open label in adolescent and adult patients with persistent stable asthma. Novartis. Principal Investigator. April 2002.

BI1182.52. Double-blind, randomized, dose optimization trial of three doses of tipranavir boosted with low dose ritonavir (TPV/RTV) in multiple antiretroviral drug-experienced subjects. Boehringer Ingelheim Pharmaceuticals, Inc. Investigator. May 2002.

MEM-MD-06. Evaluation of the long term safety and efficacy of memantine in the treatment of chronic pain in patients with painful diabetic neuropathy. Forest Laboratories. Principal Investigator. June 2002.

AI424900. Atazanavir (BMS-232632) for HIV infected individuals: An early access program. Bristol-Myers Squibb. Investigator. July 2002.

MEM-MD-06B. Evaluation of the long term safety and efficacy of memantine in the treatment of chronic pain in patients with painful diabetic neuropathy. Forest Laboratories Principal Investigator. 2002.

ZOL446H2310 (zoledronic acid). Multinational, multicenter, double-blind, randomized, placebo controlled, parallel group study assessing the efficacy of intravenous zoledronic acid in preventing subsequent osteoporotic fractures after a hip fracture. Novartis. Principal Investigator. June 2002.

BI1182.17. A long term open label rollover trial assessing the safety and tolerability of combination tipranavir and ritonavir use in HIV-1 infected subjects. Boehringer Ingelheim Pharmaceuticals, Inc. Investigator August 2002.

MEM-MD-06C. Evaluation of the long term safety and efficacy of memantine in the treatment of chronic pain in patients with painful diabetic neuropathy. Forest Laboratories. Principal Investigator. 2002.

RESEARCH

MV16812. Multicenter, open-label, early access program of fuzeon (enfuvirtide) T-20/Ro29-9800, HIV-1 Fusion Inhibitor) in combination with free choice antiretroviral regimen to assess serious adverse events, serious AIDS defining events, and tolerability in patients with advanced HIV-infection. F. Hoffmann-LaRoche LTD, Trimeris Inc., Investigator.

SAS30031. A randomized, double-blind, 12 week trial evaluating the safety of Fluticasone Propionate/Salmeterol Diskus combination product 100/50mcg bid versus Fluticasone Propionate Diskus 100mcg bid in symptomatic pediatric subjects (4 – 11 years) with asthma. GlaxoSmithKline. Principal Investigator. 2002.

BY217/FK1 020. 12 week treatment with 250mcg Roflumilast versus placebo in patients with asthma. Byk Gulden Pharmaceuticals. Principal Investigator. 2002.

BA16630B. Inhaled corticosteroid replacement study- Efficacy and safety of Ro-27-2441 in moderate persistent asthma. Phase II. Hoffmann La Roche. Principal Investigator. Dec. 2002.

BA16631B. Dose –ranging study of Ro 27-2441 in patients with persistent asthma not treated with inhaled corticosteroids - Phase II. Hoffman La Roche. Principal Investigator. Dec. 2002.

BI1182.12. Randomized, open-label, comparative safety and efficacy study of tipranavir boosted with low-dose ritonavir (TPV/RTV) versus genotypically-defined protease inhibitor/ritonavir (PI/RTV) in multiple antiretroviral drug-experienced patients (RESIST-1: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients with Tipranavir). Boehringer Ingelheim Pharmaceuticals, Inc. Investigator. Jan 2003.

BI1182.51. An open label, randomized, parallel group pharmacokinetics trial of tipranavir/ritonavir (TPV/RTV), alone or in combination with RTV-boosted saquinavir (SQV), amprenavir (APV) or lopinavir (LPV), plus an optimized background regimen, in multiple antiretroviral (ARV) experienced patients. Boehringer Ingelheim Pharmaceuticals, Inc. Investigator. Jan 2003.

CVAH631C2301. A randomized, double-blind, multicenter, placebo-controlled, parallel group study to evaluate the efficacy and safety of valsartan (320mg) and hydrochlorothiazide (12.5mg and 25mg) combined and alone, valsartan 160mg and valsartan 160mg/hydrochlorothiazide 12.5mg in hypertensive patients. Novartis Pharmaceuticals. Principal Investigator. 2003.

RESEARCH

CVAH631C2301. Pharmacogenetic Substudy . A randomized, double-blind, multicenter, placebo-controlled, parallel group study to evaluate the efficacy and safety of valsartan (320mg) and hydrochlorothiazide (12.5mg and 25mg) combined and alone, valsartan 160mg and valsartan 160mg/hydrochlorothiazide 12.5mg in hypertensive patients. Novartis Pharmaceuticals. Principal Investigator. 2003.

CVAH631C2301. A 54-week open-label extension to a randomized, double-blind, multicenter, placebo-controlled, parallel group study to evaluate the efficacy and safety of valsartan (320mg) and hydrochlorothiazide (12.5mg and 25mg) combined and alone, valsartan 160mg and valsartan 160mg/hydrochlorothiazide 12.5mg in hypertensive patients. Novartis Pharmaceuticals. Principal Investigator. 2003.

A3841012. Clinical utility of amlodipine/atorvastatin to improve concomitant cardiovascular risk factors of hypertension and dyslipidemia (Gemini). Pfizer. Principal Investigator. 2003.

CHTF919A2306. A randomized, double-blind, placebo-controlled, parallel group, multicenter study to assess the efficacy and safety of repeated treatment with tegaserod 6mg bid and placebo in female patients with irritable bowel syndrome with constipation (IBS-C). Novartis. Principal Investigator. July 2003.

BY217/M2-023. A randomized, controlled study of roflumilast (250mcg and 500mcg) versus placebo in patients with asthma. A 24-week, multinational, double-blind, parallel group clinical study. Altana. Principal Investigator. 2003

D5896C0005. A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT[®] pMDI administered either as fixed or as an adjustable regimen versus a fixed regimen of Advair[™] in subjects 12 years of age and older with asthma. Astra Zeneca. Principal Investigator. 2003.

C02-009. A phase III, randomized, multicenter, allopurinol and placebo-controlled study assessing the safety and efficacy of oral febuxostat in subjects with gout. TAP Pharmaceuticals. Principal Investigator. 2003

CCIB002 K2302. A randomized, double-blind, multicenter, positive controlled, parallel group study to evaluate the safety and efficacy of Lotrel (amlodipine/benazepril) compared to Zestoretic (lisinopril/hydrochlorothiazide) in hypertensive patients. Novartis Pharmaceuticals. Principal Investigator. 2003.

RESEARCH

066-00. A randomized, double-blind, active-comparator-controlled, parallel-group study to evaluate the safety of etoricoxib in patients with osteoarthritis or rheumatoid arthritis. Merck. Principal Investigator. 2003.

MK-038. A multicenter, randomized, double-blind, placebo-controlled, “factorial design study to evaluate the lipid-altering efficacy and safety of ezetimibe/simvastatin combination tablet in patients with primary hypercholesterolemia. Merck. Principal Investigator. 2003.

D5896C00005. A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of Symbicort^R pMDI administered either as fixed or as an adjustable regimen versus a fixed regimen of Advair^R in subjects 12 years and older with asthma. AstraZeneca. Principal Investigator. January 2004.

4522US/0011. A randomized, double-blind, placebo-controlled, multicenter, phase III study of Rosuvastatin (Crestor) 20 mg in the primary prevention of cardiovascular events among subjects with low levels of LDL-Cholesterol and elevated levels of C-reactive protein. AstraZeneca. Principal Investigator. July 2004.

NN210005. A phase I, multicenter, randomized, parallel, double-blinded dose ranging, placebo-controlled study to compare antiviral effect, safety, tolerability and pharmacokinetics of four oral dosage regimens of GW695634G monotherapy versus placebo over 7 days in NNRTI-experienced HIV-1 infected adults. GlaxoSmithKline. Investigator. July 2004.

CCOX189A2369. A 52-week, international, multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial to compare retention on treatment, safety, tolerability and efficacy of lumiracoxib 100mg od, lumiracoxib 100mg bid and celecoxib 200mg od in patients with primary osteoarthritis of hip, knee, hand or spine. Novartis Pharmaceuticals. Principal Investigator. July 2004.

D5896C00001. A randomized, double-blind, active-controlled, parallel-group, single-dummy, multicenter, 12 week study to assess the efficacy and safety of Symbicort pMDI 160/4.5 ug x 2 actuations once-daily (QD) compared to symbicort pMDI 80/4.5 ug x 2 actuations QD, Symbicort pMDI 80/4.5 ug x 2 actuations twice-daily (BID) and to budesonide pMDI 160 ug x 2 actuations QD in asthmatic subjects 12 years of age and older. AstraZeneca Pharmaceuticals LP. Principal Investigator. July 2004.

RESEARCH

BI1182.58. An open label safety study to evaluate the safety of tipranavir plus ritonavir when used in combination with other agents for the treatment of patients with HIV infection who have failed and/or are intolerant to combination antiretroviral therapy and have limited treatment options. Boehringer Ingelheim. Investigator. 2004.

L8890. Prospective, observational registry and patient survey of the management of men with symptomatic benign prostatic hyperplasia (BPH): BPH registry and patient survey. Sanofi. Investigator. September 2004.

ML18018D. A 12-week, prospective, open-label, multicenter, cohort study to assess HIV-patient quality of life and tolerability after administration of enfuvirtide-containing HAART (Qualite). Roche. Investigator. December 2004.

BI1182.70. An open label, non-randomized treatment protocol of tipranavir co-administered with low-dose ritonavir (TPV/r) in protease inhibitor-experienced patients with HIV-1 infection (the tipranavir expanded access program). Boehringer Ingelheim. Investigator. December 2004.

COL102060. An open-label, multicenter study to evaluate the efficacy and safety of a fixed-dose combination of abacavir 600mg/lamivudine 300mg once-daily in combination with atazanavir 300mg + ritonavir 100mg once-daily in antiretroviral-naïve HIV-1 infected subjects over 48 weeks. GlaxoSmithKline. Investigator. December 2004.

HMR3647A/4019. A randomized, double-blind, parallel-group, multicenter study to compare clinical health outcomes of telithromycin versus azithromycin in outpatients with community-acquired lower respiratory tract infections. Aventis. Investigator. February 2005.

CCR102881. A Phase IIb, 96 week, randomized, partially double-blinded, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW873140 in combination with COMBIVIR (lamivudine and zidovudine) upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naïve adults. GlaxoSmithKline. Investigator. March 2005.

CCR104627. A screening protocol to determine eligibility for one of three Phase III treatment studies evaluating the efficacy and safety of GW873140 in R5-tropic and R5/X4-tropic HIV-1 infected, treatment-experienced subject with drug-resistant virus or an observational study in X4-tropic or non-phenotypeable HIV-1 infected, treatment-experienced subjects with drug-resistance virus. GlaxoSmithKline. Investigator. July 2005.

RESEARCH

U10-04-02-007. A randomized, double-blind, placebo-controlled, multicenter, pilot study to evaluate the safety and analgesic activity of M40403 co-administered with an opioid agent in a cancer pain model. Metaphore Pharmaceuticals. Principal Investigator. July 2005.

CVAH631BUS04/A. A 28 week, multicenter, randomized, active controlled, parallel group study to evaluate the effects of Diovan HCT (160/12.5 mg) in comparison with hydrochlorothiazide (25 mg) monotherapy, for the treatment of patients with hypertension, uncontrolled by hydrochlorothiazide (12.5 mg) monotherapy. Novartis. Principal Investigator. August 2005.

CSPP100A2328. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study comparing an eight week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis. Principal Investigator. August 2005.

HPR20001. A phase IIb, randomized, multicenter, parallel group study to evaluate the short-term safety, pharmacokinetics and antiviral activity of four blinded dosing regimens of GW640385/ritonavir therapy compared to open-label current protease inhibitor therapy in HIV-1 infected, protease inhibitor experienced adults for 2 weeks with long-term evaluation (>48 weeks) of safety, pharmacokinetic and antiviral activity of selected GW640385/ritonavir dosing regimen(s) vs. a ritonavir-boosted, protease inhibitor containing regimen. GlaxoSmithKline. Investigator. October 2005.

TMC114-C211. A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects. ARTEMIS TRIAL. Tibotec Pharmaceuticals Ltd. Investigator. November 2005.

TMC114-C226. Early access of TMC114 in combination with low-dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options. Tibotec Pharmaceuticals Ltd. Investigator. November 2005.

M05-750. A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of fenofibric acid and atorvastatin calcium combination therapy to fenofibric acid and atorvastatin calcium monotherapy in subjects with mixed dyslipidemia. Abbott Laboratories. Investigator. December 2005.

M05-758. A long-term, open-label, safety extension study of the combination of fenofibric acid and statin therapy for subjects with mixed dyslipidemia. Abbott Laboratories. Investigator. December 2005.

RESEARCH

D5899C00001. A 12 month double-blind, double-dummy, randomized parallel group, multicenter efficacy and safety study of SYMBICORT® pMDI 2 x 160/4.5 mcg bid and 2 x 80/4.5 mcg bid compared to Formoterol TBH 2 x 4.5 mcg bid and placebo in patients with COPD. AstraZeneca. Investigator. March 2006.

References available upon request